Atg13 Inhibitors
The chemical class of ATG13 Inhibitors, while not directly targeting ATG13, focuses on modulating the ULK complex and other key components involved in the initiation and regulation of autophagy. Autophagy is a cellular degradation process that is essential for maintaining cellular homeostasis, particularly under stress conditions. ATG13, as part of the ULK complex, plays a vital role in the early steps of autophagy initiation, responding to nutrient status and cellular energy levels.
The inhibitors listed predominantly target kinases like ULK1/2 or mTOR, or affect processes downstream in autophagy, such as lysosomal function or PI3K activity. For example, SBI-0206965 and MRT67307 inhibit ULK1 and ULK2, directly impacting the ULK complex's role in autophagy initiation. Chloroquine and Bafilomycin A1, on the other hand, act later in the autophagy pathway, inhibiting lysosomal degradation and autophagosome-lysosome fusion, respectively. Their indirect effect on ATG13's function is through the disruption of the autophagic flux. Additionally, compounds like Rapamycin and Torin 1, which inhibit mTOR, indirectly promote autophagy, thereby influencing the function of the ATG13-containing ULK complex. mTOR is a critical nutrient sensor and a central regulator of cell growth and metabolism, and its inhibition releases the suppression on the ULK complex, facilitating autophagy initiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SBI-0206965 | 1884220-36-3 | sc-507431 | 10 mg | $124.00 | ||
SBI-0206965 is a selective inhibitor of ULK1, a key kinase in the ULK complex. By inhibiting ULK1, it indirectly affects ATG13, which is a part of the same complex involved in initiating autophagy. | ||||||
MRT67307 | 1190378-57-4 | sc-507433 | 10 mg | $234.00 | ||
MRT67307 is a dual inhibitor of ULK1/2 and TBK1. Since ULK1 and ULK2 are central to the function of the ATG13-containing ULK complex, inhibiting these kinases indirectly impacts ATG13’s role in autophagy. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is a well-known autophagy inhibitor that raises the lysosomal pH, thereby impairing lysosomal degradation. Though it does not directly target ATG13, it inhibits the downstream effects of autophagy. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine (3-MA) inhibits class III PI3K, which is involved in autophagy initiation. By doing so, it indirectly affects the function of ATG13 in the ULK complex. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting class III PI3K, it can indirectly influence ATG13's role in the ULK complex, as PI3K activity is crucial for autophagy induction. | ||||||
SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
SAR405 is a specific inhibitor of the Vps34 PI3K, which plays a role in autophagy. Its inhibition can indirectly affect ATG13's function in the ULK complex involved in autophagy initiation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is an mTOR inhibitor. Since mTOR is a negative regulator of the ULK complex, Torin 1’s inhibition of mTOR can indirectly promote the function of ATG13 in autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a broad-spectrum inhibitor of PI3K. By inhibiting PI3K, it indirectly impacts the function of ATG13 in the ULK complex, as PI3K activity is important for autophagy initiation. | ||||||
MHY1485 | 326914-06-1 | sc-507522 | 10 mg | $140.00 | ||
MHY1485 is an mTOR activator. By activating mTOR, it indirectly inhibits the ULK complex including ATG13, since mTOR is a negative regulator of autophagy. | ||||||